Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $28.83

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $28.83.

Several equities research analysts recently weighed in on the company. Lifesci Capital upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, October 22nd. JMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Wedbush restated an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. UBS Group assumed coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a "buy" rating and a $27.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research note on Wednesday.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in shares of Kura Oncology during the 3rd quarter valued at about $25,000. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter worth $110,000. Quarry LP bought a new stake in Kura Oncology during the second quarter valued at about $196,000. Entropy Technologies LP bought a new stake in Kura Oncology during the first quarter valued at about $218,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company's stock valued at $288,000 after acquiring an additional 5,788 shares in the last quarter.

Kura Oncology Trading Down 0.5 %

NASDAQ KURA traded down $0.09 on Friday, hitting $17.68. The company's stock had a trading volume of 687,009 shares, compared to its average volume of 660,457. The firm has a market cap of $1.35 billion, a P/E ratio of -7.49 and a beta of 0.86. Kura Oncology has a 52-week low of $8.17 and a 52-week high of $24.17. The company's 50-day simple moving average is $18.78 and its 200 day simple moving average is $20.00. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same quarter in the prior year, the firm posted ($0.53) earnings per share. The firm's revenue was up .0% compared to the same quarter last year. Research analysts predict that Kura Oncology will post -2.46 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.